Lansoprazole

Lansoprazole, the active ingredient in Lansoprazole, is a proton pump inhibitor presented as an oral tablet for oral use. It treats acid‑related disorders such as gastro‑esophageal reflux disease, peptic ulcer disease and erosive esophagitis in adult patients.

GNH USA supplies Lansoprazole as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is used to manage conditions associated with excess gastric acid secretion.

- Gastro‑esophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of esophageal irritation. - Peptic ulcer disease: facilitates ulcer healing and helps prevent recurrence. - Erosive esophagitis: heals erosive lesions and reduces further damage. - Helicobacter pylori eradication (as part of combination therapy): enhances eradication rates when combined with appropriate antibiotics.

Adverse reactions to lansoprazole vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: watery stools, usually transient. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: severe colitis presenting with diarrhea. - Hypomagnesemia: low magnesium levels with prolonged use. - Stevens‑Johnson syndrome: severe skin and mucous membrane reactions. - Interstitial nephritis: inflammation of kidney tissue. - Elevated liver enzymes: signs of hepatic stress.

Before initiating lansoprazole therapy, consider the following precautions.

- Assess renal function: adjust use in patients with severe renal impairment. - Monitor magnesium levels: prolonged therapy may lead to hypomagnesemia. - Use cautiously in liver disease: monitor hepatic function tests. - Evaluate bleeding risk: gastric acid suppression can affect platelet function. - Pregnancy and lactation: prescribe only if potential benefit justifies potential risk. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Lansoprazole may alter the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atorvastatin: increased plasma concentration, raising risk of myopathy. - Methotrexate: elevated serum levels, potentially causing toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring closer anticoagulation monitoring. - Digoxin: may raise serum digoxin concentrations, necessitating dose adjustment.